Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

 

(Amendment No. 1)*

 

 

CASI Pharmaceuticals, Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

14757U 109

(CUSIP Number)

December 31, 2016

(Date of Event Which Requires Filing of the Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o

Rule 13d-1(b)

 

x

Rule 13d-1(c)

 

o

Rule 13d-1(d)

 

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

Cusip No.14757U 109

13G

Page 2 of 5 Pages

 

 

1.	NAME OF REPORTING PERSONS   ZHEJIANG KANGLAITE GROUP CO., LTD
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) o (b) o
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION   HANGZHOU CITY, ZHEJIANG PROVINCE, CHINA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER   4,938,269
	6.	SHARED VOTING POWER
	7.	SOLE DISPOSITIVE POWER   4,938,269
	8.	SHARED DISPOSITIVE POWER

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   4,938,269
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)   o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)   8.09%
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)   OO

 

 

Cusip No.14757U 109

13G

Page 3 of 5 Pages

 

 

Item 1(a).	Name of Issuer:
	CASI Pharmaceuticals, Inc.
Item 1(b).	Address of Issuer’s Principal Executive Offices:
	9620 Medical Center Drive, Suite 300, Rockville, MD 20850
Item 2(a).	Name of Person Filing:
	ZHEJIANG KANGLAITE GROUP CO., LTD
Item 2(b).	Address of Principal Business Office or, if none, Residence:
	ZHEJIANG KANGLAITE GROUP CO., LTD No. 16 Street, Xiasha Economic & Technical Development Zone, Hangzhou, Zhejiang, China 31008
Item 2(c).	Citizenship:
	China
Item 2(d).	Title of Class of Securities:
	Common Stock
Item 2(e).	CUSIP Number:
	14757U 109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:              N/A
	(a)	o	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
	(b)	o	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
	(c)	o	Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
	(d)	o	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
	(e)	o	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
	(f)	o	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
	(g)	o	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
	(h)	o	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	o	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
	(j)	o	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
	(k)	o	Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

 

 

 

Cusip No.14757U 109

13G

Page 4 of 5 Pages

 

 

Item 4.	Ownership:
	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

	(a)	Amount beneficially owned: 4,938,269
	(b)	Percent of class: 8.09%
	(c)	Number of shares as to which the person has:
		(i)	Sole power to vote or to direct the vote: 4,938,269
		(ii)	Shared power to vote or to direct the vote:
		(iii)	Sole power to dispose or to direct the disposition of: 4,938,269
		(iv)	Shared power to dispose or to direct the disposition of:

 

Item 5.	Ownership of Five Percent or Less of a Class:
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.
Item 6.	Ownership of More Than Five Percent on Behalf of Another Person:
	N/A
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
	N/A
Item 8.	Identification and Classification of Members of the Group:
	N/A
Item 9.	Notice of Dissolution of Group:
	N/A
Item 10.	Certifications:
	N/A

 

 

Cusip No.14757U 109

13G

Page 5 of 5 Pages

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:

March 3, 2017

 

 

By:        /s/ Li Dapeng                         

 

Name:   Li Dapeng

 

Title:     Chairman